<DOC>
	<DOCNO>NCT01574651</DOCNO>
	<brief_summary>This study ass efficacy safety QVA149 compare tiotropium plus formoterol patient moderate severe COPD .</brief_summary>
	<brief_title>The Effect QVA149 Health Related Quality Life Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female adult age ≥ 40 yr Patients moderate severe chronic obstructive pulmonary disease ( GOLD 2010 guideline ) Smoking history least 10 pack year Postbronchodilator FEV1 &lt; 80 % ≥30 % predict normal value postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Pregnant woman nurse mother woman childbearing potential use adequate contraception Patients history long QT syndrome Patients Type I uncontrolled Type II diabetes Patients COPD exacerbation respiratory tract infection within 6 week prior screen Patients history asthma Patients pulmonary lobectomy , lung volume reduction surgery , lung transplantation Patients concomitant pulmonary disease Patients require long term oxygen therapy ( &gt; 15 h day ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>QVA149</keyword>
	<keyword>Health related quality life</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Tiotropium</keyword>
	<keyword>COPD</keyword>
</DOC>